OncoGenex Pharmaceuticals Inc (OGXI.OQ)
9 Dec 2016
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|68||2010||Independent Chairman of the Board|
|49||2013||President, Chief Executive Officer, Treasurer, Secretary, Director|
|38||2014||Chief Financial Officer, Vice President|
|57||2008||Executive Vice President, Chief Medical Officer|
- BRIEF-Oncogenex Pharmaceuticals says committed to further reduction in workforce
- BRIEF-Oncogenex Pharmaceuticals reports Q3 loss per share $0.12
- BRIEF-Oncogenex says will cut about 55 pct of company's workforce
- BRIEF-OncoGenex announces positive survival results from apatorsen Phase 2 trial in metatstatic bladder cancer
- BRIEF-Oncogenex says phase 3 ENSPIRIT trial of custirsen in non-small cell lung cancer did not meet primary endpoint